Zurich immuno-oncology spinout Anaveon raised $35.1m from Novartis Venture Fund and Syncona in addition to seed-stage notes converted by the UZH Life Sciences Fund.

Russian Academy of Sciences spinout PM&HM has signed up a second government-owned vehicle to help commercialise its digitally-enabled inhaler for tuberculosis, cancer and HIV.

NIH will provide $3.5m to establish a human health-focused accelerator in five US states, with space for five biotech projects in its initial cohort.

Geneos Therapeutics has received $10.5m in series A funding from investors including its parent company Inovio Pharmaceuticals.

The private equity firm’s latest fund has closed with $2.1bn from backers including endowments for specialty materials, chemicals and pharmaceuticals investments.

Spark Therapeutics publicly listed in 2015 and is set to net Children's Hospital of Philadelphia up to $458m following its acquisition by Roche.

Lilly Asia Ventures has contributed to an $85m series B round for Gracell Biotechnologies, whose shareholders also include 6 Dimensions Capital.

Fraunhofer Venture has unveiled an accelerator for businesses based on its research in areas including artificial intelligence, digital medicine and industry 4.0.

Taikang and WuXi-backed CStone Pharmaceuticals has priced its shares near the middle of its proposed range to raise $285m in proceeds at a valuation of $1.5bn.

Rare disease diagnosis technology developer Centogene is gearing up for an IPO having spun out from Rostock in 2006 and raised $28.5m of equity funding in 2017.